Hepatitis B cost-effectiveness of therapy

Hepatitis Main Page
Hepatitis B
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Hepatitis B from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Treatment
Medical Therapy
Surgery
Primary Prevention
Hepatitis B Vaccination
Hepatitis B Vertical transmission
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatitis B cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatitis B cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatitis B cost-effectiveness of therapy
CDC on Hepatitis B cost-effectiveness of therapy
Hepatitis B cost-effectiveness of therapy in the news
Blogs on Hepatitis B cost-effectiveness of therapy
Directions to Hospitals Treating Hepatitis B
Risk calculators and risk factors for Hepatitis B cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Given the risk of complications (e.g., cirrhosis or hepatocellular carcinoma) in infants and young children who are infected with the HBV, as well as the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective.